|Day's range||0.7000 - 0.7000|
Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.
After losing some value lately, a hammer chart pattern has been formed for Novartis (NVS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease stage, menopausal or nodal status1 Results were also consistent across all secondary endpoints, including distant disease-free survival and recurrence-free survival, with a trend for improved overall survival*1 The safety profile of Kisqali was favorable at 400 mg with low rates of symptomatic adv
Bayer (BAYRY) announces licensing agreement with Cedilla Therapeutics to jointly develop and commercialize the latter's selective protein complex inhibitors as novel cancer therapies.
Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
Sandoz AG to remain based in Basel, Switzerland following proposed spin-off from Novartis Announcement of planned city-center HQ marks important milestone as Sandoz prepares to become independent company Basel, as a global life sciences center, ideally located to attract top talent Basel, June 1, 2023 — Sandoz AG, a global leader in generic and biosimilar medicines, has announced the location of its future permanent headquarters in central Basel. The Sandoz AG headquarters plans to move to a lan
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.
Here is how Adma Biologics (ADMA) and Novartis (NVS) have performed compared to their sector so far this year.
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.
Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.
Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, prevention of skeletal related complications in cancer that has spread to the bone and unresectable giant cell tumor of the bone1,2 Sandoz continues to build its biosimilars portfolio to increase patient access to high-
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis have been highlighted in this Screen of The Week article.
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
Dividend stocks W.W. Grainger (GWW), Graphic Packaging (GPK), PulteGroup (PHM), Walmart (WMT) and Novartis (NVS) could be solid choices for your portfolio.
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.